You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖-B(02696.HK):委任張文傑為首席執行官,持續推動創新與國際化戰略佈局
格隆匯 09-30 16:59

格隆匯9月30日丨復宏漢霖-B(02696.HK)公佈,ScottShi-Kau Liu博士因個人工作重心調整的原因已呈請辭任公司執行董事、董事會戰略委員會委員、環境、社會及管治委員會委員及公司首席執行官,自2020年9月30日起生效。辭任後LIU博士將擔任公司的戰略諮詢委員會主任,關注公司研發方向、公司戰略的制定以及團隊建設和發展。

張文傑先生已獲提名出任第二屆董事會執行董事,待公司股東於臨時股東大會上批准後,方可作實,並自2020年9月30日起獲委任為公司首席執行官。張先生作為公司首席執行官兼總裁將帶領高級管理團隊進行公司日常管理,並監督公司及其附屬公司的營運。

張先生,52歲,自2019年3月至2020年2月擔任公司高級副總裁、首席商業運營官及首席戰略官,並自2020年2月起擔任公司總裁、公司全資附屬公司上海復宏漢霖生物製藥有限公司總裁、上海復宏漢霖生物醫藥有限公司總裁,負責集團運營管理,着力搭建集團創新商業運營模式,打造國際化戰略佈局,併成功推動集團核心產品HLX02注射用曲妥珠單抗(中國境內商品名:漢曲優)的順利上市。

張先生於醫藥行業擁有逾25年商業運營及管理經驗。在加入公司之前,張先生曾擔任安進中國的總經理、中國上海羅氏製藥有限公司腫瘤業務二部副總裁、中國拜耳先靈特藥及腫瘤部負責人等。張先生於1990年7月自中國山東大學獲得微生物學學士學位,並於1998年5月自美國耶魯大學獲得工商管理碩士學位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account